Table 2. Characteristics of patients according to the presence of TERT promoter (−124 G>A and −146 G>A) and CTNNB1 exon 3 mutations.
| Characteristics | TERT −124 G>A and −146 G>A | P | CTNNB1 exon 3 | P |
|---|---|---|---|---|
| (n = 65) (%) | (n = 33) (%) | |||
| Sex | 0.832 | 0.680 | ||
| Males (n = 102) | 50 (49.0) | 26 (25.5) | ||
| Females (n = 32) | 15 (46.8) | 7 (21.9) | ||
| Age | 0.437 | 0.754 | ||
| ≤ 60 (n = 22) | 9 (40.9) | 6 (27.3) | ||
| > 60 (n = 112) | 56 (50.0) | 27 (24.1) | ||
| Tumor Size | 0.288 | 0.914 | ||
| < 5 cm (n = 72) | 38 (52.7) | 18 (25.0) | ||
| ≥ 5 cm (n = 62) | 27 (43.5) | 15 (24.2) | ||
| Grading | 0.175 | |||
| G1 (n = 1) | 1 (100) | 1 (100) | 0.246 | |
| G2 (n = 129) | 63 (48.8) | 31 (24.1) | 0.596 | |
| G3 (n = 3) | 0 | 1 (33.3) | 1.000 | |
| G4 (n = 1) | 1 (100) | 0 | 1.000 | |
| Staging | 0.173 | 0.267 | ||
| <Stage III (n = 64) | 35 (54.7) | 13 (20.3) | ||
| ≥Stage III (n = 70) | 30 (42.8) | 20 (28.6) | ||
| AFP | 0.130 | 0.188 | ||
| ≤20 ng/ml (n = 55) | 31 (56.4) | 16 (29.1) | ||
| >20 ng/ml (n = 79) | 34 (43.1) | 17 (21.5) | ||
| Tumor sites | 0.900 | 0.102 | ||
| Single (n = 90) | 44 (48.8) | 26 (28.8) | ||
| Multiple (n = 44) | 21 (47.7) | 7 (15.9) | ||
| Etiology | ||||
| HCC HBV+ (n = 12)* | 5 (41.7) | 0.620 | 2 (16.7) | 0.730 |
| HCC HCV+ (n = 110) | 59 (53.6) | <0.0001 | 29 (26.4) | 0.320 |
| HCC No viral (n = 5) | 0 | 0.058 | 2 (40.0) | 0.596 |
| HCC-CC HBV+ (n = 1) | 0 | 0 | ||
| HCC-CC HCV+ (n = 2) | 0 | 0 | ||
| CC HCV+ (n = 4) | 1 (25.0) | 0 | ||
| Event | 0.368 | 0.036† | ||
| Survival >2 years (n = 21) | 13 (61.9) | 9 (42.9) |
*
This group comprises two cases of HBV+/HCV+ cases
†
Log Rank test has been used to compare the survival distributions of mutated and non-mutated cases.